Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Net profit attributable to equity shareholders of the parent company fell 35.6% year on year to Rs 925 crore from Rs 1,437.2 crore in Q2 FY26. Sequentially, net profit rose 108.6% from Rs 443.5 crore in Q1 FY27.
Gross profit declined 6.1% year on year to Rs 4,520.4 crore from Rs 4,814 crore. Gross margin narrowed to 52.1% from 54.7% a year earlier, but improved from 46.5% in Q1 FY27.
Profit before tax declined 33.1% year on year to Rs 1,227.7 crore from Rs 1,835 crore in Q2 FY26. It rose 122.2% quarter on quarter from Rs 552.6 crore in Q1 FY27.
The company reported EBITDA of Rs 1,783 crore, with a margin of 20.6%, and a net cash surplus of Rs 2,502 crore. EBITDA declined 24% year on year and increased 77% quarter on quarter. Q1 FY27 was impacted by a Rs 240 crore provision for inventory and other costs related to the semaglutide API issue.
Selling, general and administrative expenses increased 6.2% year on year to Rs 2,807.5 crore, while research and development expenses declined 15.6% to Rs 523.5 crore.
The global generics business recorded revenue of Rs 7,792.7 crore, down 0.7% year on year but up 8.2% quarter on quarter. North America revenue fell 23.2% year on year to Rs 2,489 crore. Emerging markets revenue rose 24.4% to Rs 2,059.5 crore, while India revenue increased 17.3% to Rs 1,850.8 crore. Europe revenue grew 1.3% to Rs 1,393.5 crore. Revenue from pharmaceutical services and active ingredients declined 12.1% to Rs 831 crore.
The company said lower lenalidomide sales in North America primarily affected quarterly revenue. Excluding lenalidomide sales in North America, its underlying base business continued to deliver double-digit growth across businesses, except Europe and active pharmaceutical ingredients, supported by favourable currency movements.
“We continued to improve the overall health of our business, delivering double-digit base business growth and EBITDA margins of over 20% during the quarter,” said G V Prasad, co-chairman and managing director. He added that the company remained focused on strengthening its core businesses, enhancing productivity and investing in strategic growth platforms.
Dr. Reddy's Laboratories is a Hyderabad-based global pharmaceutical company offering APIs, generics, branded generics, biosimilars and OTC products. Its key therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Major markets include the US, India, Russia and CIS countries, China, Brazil and Europe.
Dr Reddy's Laboratories shares jumped 5.88% to Rs 1,296.50 on the BSE.
Dr Reddys Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 1243, up 1.8% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.48% on the day, quoting at 22670.45. The Sensex is at 72404.26, down 0.5%. Dr Reddys Laboratories Ltd has gained around 7.67% in last one month.
Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has gained around 1.12% in last one month and is currently quoting at 26761.65, up 0.45% on the day. The volume in the stock stood at 34.38 lakh shares today, compared to the daily average of 14.98 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 1241.9, up 1.45% on the day. Dr Reddys Laboratories Ltd is up 1.58% in last one year as compared to a 7.89% slide in NIFTY and a 25.3% slide in the Nifty Pharma index.
The PE of the stock is 153.77 based on TTM earnings ending June 26.
Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 1213, up 0.17% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.51% on the day, quoting at 23448.85. The Sensex is at 74923.95, up 0.53%. Dr Reddys Laboratories Ltd has risen around 1.93% in last one month.
Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has risen around 2.32% in last one month and is currently quoting at 26909.6, up 0.15% on the day. The volume in the stock stood at 5.57 lakh shares today, compared to the daily average of 14.49 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 1213.1, up 0.51% on the day. Dr Reddys Laboratories Ltd is down 6.56% in last one year as compared to a 6.42% drop in NIFTY and a 21.5% drop in the Nifty Pharma index.
The PE of the stock is 152.45 based on TTM earnings ending June 26.
Dr Reddys Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1208.6, up 1.99% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.29% on the day, quoting at 23413.6. The Sensex is at 74819.64, up 0.71%. Dr Reddys Laboratories Ltd has added around 1.56% in last one month.
Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has added around 2.67% in last one month and is currently quoting at 26710.1, up 1.25% on the day. The volume in the stock stood at 8.06 lakh shares today, compared to the daily average of 13.35 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 1205.2, up 1.8% on the day. Dr Reddys Laboratories Ltd is down 7.13% in last one year as compared to a 7.1% fall in NIFTY and a 20.91% fall in the Nifty Pharma index.
The PE of the stock is 147.31 based on TTM earnings ending June 26.
The collaboration follows the approval of QDENGA's marketing authorization by India's Central Drugs Standard Control Organization (CDSCO) in July 2026 for individuals aged 4-60 years. As India's first approved dengue vaccine, the approval marks an important milestone in the country's efforts to strengthen dengue prevention and management.
Market participants are assessing a slew of Q1 FY27 earnings announcements, with sector- and stock-specific movements remaining in focus amid the ongoing earnings season while keeping a close watch the progress of the monsoon. The Nifty traded below the 24,500 level.
Investors are closely tracking the domestic inflation data due on Wednesday, alongside crude oil price movements and developments on the global geopolitical front, for further cues on the market’s near-term direction.
Media, FMCG and metal shares declined while consumer durables, IT and PSU Bank shares advanced.
At 13:25 IST, the barometer index, the S&P BSE Sensex declined 368.68 points or 0.47% to 78,173.09. The Nifty 50 index dropped 121.25 points or 0.49% to 24,462.70.
In the broader market, the BSE 150 MidCap Index declined 0.10% and the BSE 250 SmallCap Index added 0.27%.
The market breadth was negative. On the BSE, 1,958 shares rose and 2,221 shares fell. A total of 223 shares were unchanged.
Gainers & Losers:
Dr Reddy Laboratories (up 3.09%), Titan Company (up 1.06%), Tata Consultancy Services (TCS) (up 0.60%), HCL Technologies (up 0.53%) and Infosys (up 0.51%) were the top gainers.
Max Healthcare (down 2.69%), Tata Consumer Products (down 2.21%), SBI Life Insurance Company (down 2.01%), Apollo Hospitals Enterprise (down 2%) and Nestle India (down 1.83%) were the top losers.
Stocks in Spotlight:
Triveni Turbine declined 5.77% after the company reported a 20.78% decline in consolidated net profit to Rs 51.1 crore, despite a 19.23% increase in revenue from operations to Rs 442.7 crore in Q1 FY27 over Q1 FY26.
Vodafone Idea rose 2.09% after reporting a strong operational performance for the quarter ended 30 June 2026. On a consolidated basis, adjusted net loss narrowed to Rs 5361.99 crore in Q1 FY27, from a loss of Rs 6608.1 crore in Q1 FY26 and a loss of Rs 5513 crore in Q4 FY26. Revenue from operations rose 6.0% YoY and 3.2% QoQ to Rs 11,689 crore during the quarter.
Bharat Forge fell 1.62% after the company reported a consolidated net loss of Rs 89.73 crore in Q1 FY27 as against a net profit of Rs 283.68 crore in Q1 FY26. Revenue for the period under review was Rs 4,639.94 crore, up 18.7% YoY.
Kolte-Patil Developers surged 15.95% after reporting strong financial performance for the quarter ended 30 June 2026. On a consolidated basis, adjusted net profit stood at Rs 146.26 crore in Q1 FY27, compared with an adjusted net loss of Rs 16.99 crore in Q1 FY26 and Rs 15.98 crore in Q4 FY26. Net sales rose 1,016.5% YoY and 269.9% QoQ to Rs 919.54 crore during the quarter.
Bosch rallied 4.49%. The company reported 36.8% fall in consolidated net profit to Rs 704.90 crore in Q1 FY27, down 36.80% from Rs 1,115.30 crore in Q1 FY26. Revenue for the period under review was Rs 5,841.90 crore, up 22% YoY. The growth in revenue was driven by higher demand in passenger cars and off-highway segment
Global Market:
European market declined amid renewed US Iran tensions along with weak UK retail data. UK retail sales growth slowed sharply in July, with total sales rising 1.3% YoY, compared with 2.5% growth a year earlier and 1.9% in June 2026. Food sales increased 3.8%, supported by the tail-end of the World Cup, while non-food sales declined 0.7%.
Asian market traded mixed on Tuesday as uncertainty continued to prevail over the global inflation outlook.
Oil prices jumped as negotiations between the U.S. and Iran over a peace deal and the reopening of the Strait of Hormuz hit an impasse.
U.S. President Donald Trump on Monday responded to Iran's conditions for a peace deal with his own demands that Iran pay compensation for people killed in wars, attacks and protests, in a rhetorical escalation likely to complicate efforts to reopen the crucial waterway.
Earlier, Iran had called for Washington to meet conditions, including recompensing Tehran for the damage caused since the U.S. and Israel launched strikes on its territory more than five months ago.
Following this development, brent crude futures rises nearly $88 per barrel and U.S. crude futures ticked up to $82.42, both the highest levels since July 31, after the contracts rallied roughly 5% on Monday.
The latest uptick in fuel costs raises the stakes for the U.S. July consumer price report due on Wednesday, where expectations are for a monthly rise of 0.1% in the headline reading and 0.2% for the core measure.
Any upside surprise could rekindle bets of a Federal Reserve rate hike next month, with the odds currently a coin toss.
Overnight on Wall Street, the Nasdaq and S&P 500 closed lower on Monday, with declines in Intel and other chipmakers, as investors became less confident about a deal to reopen the Strait of Hormuz.
The S&P 500 declined 0.06% to end the session at 7,753.12 points. The Nasdaq declined 0.32% to 26,605.36 points, while the Dow Jones Industrial Average declined 0.11% to 53,976.04 points.